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A multi-omics study links TNS3 and SEPT7 to long-term
former smoking NSCLC survival
Sipeng Shen 1,2,3,16, Yongyue Wei1,3,16, Yi Li4, Weiwei Duan5, Xuesi Dong1,6, Lijuan Lin1,6, Dongfang You1,6, Adonina Tardon 7,
Chu Chen8, John K. Field 9, Rayjean J. Hung 10, Geoffrey Liu11, Dakai Zhu12, Christopher I. Amos 12, Li Su6, Yang Zhao1,3,
Zhibin Hu2,3,13,14, Hongbing Shen3,13,14, Ruyang Zhang 1,3✉, Feng Chen 1,2,3,14,17✉ and David C. Christiani 6,15,17✉
The genetic architecture of non-small cell lung cancer (NSCLC) is relevant to smoking status. However, the genetic contribution of
long-term smoking cessation to the prognosis of NSCLC patients remains largely unknown. We conducted a genome-wide
association study primarily on the prognosis of 1299 NSCLC patients of long-term former smokers from independent discovery
(n= 566) and validation (n= 733) sets, and used in-silico function prediction and multi-omics analysis to identify single nucleotide
polymorphisms (SNPs) on prognostics with NSCLC. We further detected SNPs with at least moderate association strength on
survival within each group of never, short-term former, long-term former, and current smokers, and compared their genetic
similarity at the SNP, gene, expression quantitative trait loci (eQTL), enhancer, and pathway levels. We identified two SNPs,
rs34211819TNS3 at 7p12.3 (P= 3.90 × 10
−9) and rs1143149SEPT7 at 7p14.2 (P= 9.75 × 10
−9), were significantly associated with
survival of NSCLC patients who were long-term former smokers. Both SNPs had significant interaction effects with years of smoking
cessation (rs34211819TNS3: Pinteraction= 8.0 × 10
−4; rs1143149SEPT7: Pinteraction= 0.003). In addition, in silico function prediction and
multi-omics analysis provided evidence that these QTLs were associated with survival. Moreover, comparison analysis found higher
genetic similarity between long-term former smokers and never-smokers, compared to short-term former smokers or current
smokers. Pathway enrichment analysis indicated a unique pattern among long-term former smokers that was related to immune
pathways. This study provides important insights into the genetic architecture associated with long-term former smoking NSCLC.
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INTRODUCTION
Non-small cell lung cancer (NSCLC) accounts for more than 85% of
lung cancer cases and is the most commonly diagnosed
malignant disease1. Tobacco smoking is a well-known environ-
mental exposure leading to lung cancer2,3 and has been found to
be linked to the majority of NSCLC deaths4. Emerging evidence
shows that NSCLC in smokers and never smokers are different and
separate entities5–7.
It is, however, less well known that former smokers who quitted
smoking long time before (e.g., >10 years), termed long-term former
smokers, may also develop lung cancer8, and NSCLC patients who
are long-term former smokers still harbor a high mortality risk9. So
far, few studies have focused on the impact of genetic architecture
on the prognosis of such a special group of patients, whose
molecular mechanism for cancer death still remains unclear.
Leveraging the well-established International Lung Cancer
Consortium (ILCCO) and Harvard Lung Cancer Study (HLCS), we
conducted a GWAS by focusing on NSCLC patients who were long-
term former smokers and identified germline genetic variants
associated with overall survival time. We detected a set of SNPs
with at least moderate association signals with survival from this
subgroup as well as from other smoking subgroups, namely, never
smokers, short-term former smokers, and current smokers.
Comparing these SNPs, we investigated the genetic similarity
across these smoking subgroups at the SNP, gene, expression
quantitative trait loci (eQTL), enhancer, and pathway levels.
RESULTS
Genetic variants are associated with survival
The genome control inflation factor (λ) for the overall population
under the additive model was estimated to be 1.079 (Supple-
mentary Fig. 1), which was comparable to a previous genome-
wide survival study10, indicating that the confounding effect
caused by population stratification was well controlled. Two
SNPs (rs34211819 at chromosome 7p12.3, and rs1143149 at
7p14.2) reached genome-wide significance among NSCLC
patients who were long-term former smokers (Fig. 1a).
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rs34211819 was in an intron region of tensin-3 (TNS3), with an
MAF of 0.35; rs1143149 was an intron variant of septin 7 (SEPT7),
with an MAF of 0.34. The regional plots (Fig. 1b, c) present a
cluster of significant prognostic SNPs that were moderately or
highly correlated with rs34211819 and rs1143149 (Supplemen-
tary Table 1). Although the chromosome locations of the
two SNPs were close, they had a very low correlation (D’=
0.017, r2= 2.27 × 10−5). The C allele of rs34211819 was
Fig. 1 Results of GWAS survival analysis. a Manhattan plot for survival analysis P values. All genetic variants were coded using an additive
model. SNPs with a minor allele frequency >5%, imputation R2 > 0.8, and Hardy–Weinberg equilibrium P > 1×10−5 were included. b, c Regional
association plots for rs34211819 in TNS3 and rs1143149 in SEPT7. The left-hand Y-axis shows −log10 transformation of the P-value of individual
SNPs plotted against the chromosomal base-pair position with an expansion of 500 kb in the flanks of the SNP position. The right-hand Y-axis
shows recombination rate estimated for European populations from HapMap Data Rel 22/phase II. d, e Kaplan–Meier survival curves for
rs34211819 and rs1143149 in NSCLC patients by 0, 1, and 2 minor alleles. HRs, 95% CI and P values were derived from Cox proportional
hazards regression models adjusted for covariates.
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significantly associated with better survival (HRdiscovery= 0.66,
95% CI: 0.56-0.78, P= 2.01 × 10−7; HRvalidation= 0.84, 95% CI:
0.73–0.96, P= 1.36 × 10−2; HRcombined= 0.73, 95% CI: 0.66–0.81,
P= 3.90 × 10−9) (Fig. 1d). In contrast, the C allele of rs1143149
was associated with worse survival (HRdiscovery= 1.42, 95% CI:
1.16–1.60, P= 2.04 × 10−6; HRvalidation= 1.33, 95% CI: 1.15–1.53,
P= 7.88 × 10−5; HRcombined= 1.36, 95% CI: 1.22–1.51, P= 9.75 ×
10−9) (Fig. 1e). The associations remained significant if SNPs were
coded in co-dominant, dominant, and recessive models (Supple-
mentary Table 2), indicating the robustness of our results toward
coding. The same conclusion held with analyses of subgroups,
defined by age, gender, histology, and clinical stage (Fig. 2a), as
both SNPs were significantly associated with survival in almost all
subgroups, except for rs1143149 among the early-stage patients.
Genetic variants interaction with years of smoking cessation
We performed a stratified analysis by years of smoking cessation
for both long-term and short-term former smokers to evaluate
the modifying effect of years of smoking cessation. As years of
smoking cessation increased, the protective effect of rs34211819
and the detrimental effect of rs1143149 on survival were both
elevated (Fig. 2b, c). These effects of two SNPs were only significant
in long-term former smokers, and not in short-term former
smokers, indicating significant heterogeneity between these two
groups (rs34211819: Pheterogeneity= 0.042; rs1143149: Pheterogeneity=
0.034). The trend test detected significant trends for both SNPs
across different subgroups (rs34211819: Ptrend= 0.003; rs1143149:
Ptrend= 0.045). Further, we detected significant interaction effects
between SNPs and years of smoking cessation, a type of
gene–environment interactions (rs34211819 × years: Pinteraction=
8.0 × 10−4; rs1143149 × years: Pinteraction= 0.003) (Fig. 2d, e).
Evidence of association with lung cancer survival from multi-
omics studies
In meta-analysis of eQTL effects from GTEx and TCGA, the two
SNPs had a significant cis-eQTL relationship with gene expression
(TNS3: β=−0.09, 95% CI: −0.16 to −0.02, P= 0.009; SEPT7: β=
0.04, 95% CI: 0.01 to 0.08, P= 0.033) (Fig. 3b). In gene expression
Fig. 2 Stratified analysis and interaction analysis with smoking cessation years. a Stratified analysis of rs34211819 (left) and rs1143149
(right) among different subgroups of long-term former smokers by age (divided by median value), gender, histology type, and clinical stage.
b, c Stratified analysis of rs34211819 and rs1143149 by different years of smoking cessation in overall NSCLC patients. The left-hand Y-axis shows
the effect size (HR and 95% CI) derived from the Cox proportional hazards regression model. d, e Interaction plot for HRs of SNPs estimated
based years of smoking cessation. The shaded area represents the 95% CI. Top histogram shows distribution of years of smoking cessation.
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survival analysis of long-term former smokers, higher expression
of TNS3 (HR= 1.84, 95% CI: 1.01–3.34, P= 0.045) and SEPT7 (HR=
1.67, 95% CI: 1.02–3.21, P= 0.023) were significantly associated
with worse survival in the TCGA database (Fig. 3c).
In DNA methylation analysis, we extracted 94 CpG probes that
were located within TNS3 and SEPT7. Two CpG sites, cg22455271
and cg07462932, had significant methylation QTL (meQTL) effects
with rs1143149 (β= -0.08, 95% CI: −0.14 to −0.01, P= 0.009,
q-FDR= 0.034) and rs34211819 (β=−0.17, 95% CI: −0.32 to
−0.02, P= 0.002, q-FDR= 0.039), respectively (Fig. 3d). They were
significantly associated with survival in long-term former smokers
(HRcg22455271= 2.40, 95% CI: 1.47–3.93, P= 2.5 × 10
−4, q-FDR=
0.001; HRcg07462932= 0.47, 95% CI: 0.30–0.74, P= 7.4 × 10
−4,
q-FDR= 0.018) (Fig. 3e and Supplementary Table 3).
We predicted the functional relevance by SNPinfo, RegulomeDB,
and HaploReg v4.1 (Supplementary Table 4). rs34211819 in TNS3
had a high score of protein binding and could bind two proteins:
B cell lymphoma 3 (BCL3) and octamer transcription factor 2 (OCT2).
In the CPTAC proteomics project, the two bound proteins BCL3 (fold
change= 1.69, P= 2.16 × 10−5) and OCT2 (fold change= 2.21, P=
3.13 × 10−13) were significantly upregulated in the lung cancer
tumor tissues compared to the adjacent normal tissues (Fig. 3f).
Genetic similarity across patients with different smoking
statuses
We first performed genetic similarity comparisons at the SNP level by
extracting moderate-to-high signals from the results of survival
analysis within different smoking subgroups. A total of 7789
independent SNPs was observed in the long-term former smokers,
which were comparable to that of never-smokers (n= 7358) but
31.4% and 85.5% more than that of short-term former smokers (n=
5343) and current smokers (n= 4198), respectively. No SNPs were
shared across the four smoking subgroups. Long-term former
smokers only had 23, 20, and 11 overlapping SNPs with never
smokers, short-term former smokers, and current smokers, respec-
tively (Fig. 4a), indicating that these significant prognostic SNPs for
Fig. 3 Multi-omics analyses for TNS3 and SEPT7. a Multi-omics analyses flowchart. We observed significant eQTL/meQTL relationship,
survival-related methylation, and expression patterns and upregulated proteins in NSCLC. b Significant eQTLs were observed for the two SNPs
and cis genes. c Kaplan–Meier survival curves for expression of both genes using TCGA long-term former smoking patients. dmeQTL boxplots
of the two CpG probes and SNPs. e DNA methylation survival analysis for the two CpG probes. f Proteins BCL3 and OCT2 bound by SNPs also
differed between tumor and normal tissues.
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NSCLC patients who were long-term former smokers seemed to
differ from those for the other smoking groups.
For gene-level comparisons, these identified SNPs were assembled
to genes within each subgroup (Fig. 4b). We identified 3,837 genes
in long-term former smokers, and 1006 genes of them were shared
with never-smokers, 22.1% more than those shared with short-term
former smokers (824 genes) and 45.8% more than with current
smokers (690 genes). A total of 187 genes were commonly shared by
all the subgroups (Supplementary Table 5). Protein-coding genes
showed these same patterns of similarity (Fig. 4c).
We further investigated the eQTL-related genes based on the
GTEx lung tissue database (Fig. 4d) and enhancers from the
FANTOM5 database (Fig. 4e). For long-term former smokers,
the same trend was observed with germline-regulated genes,
which may indicate the higher similarity with never-smoking
subgroup than others. Only two eQTL-related genes were shared
among all subgroups: ARHGAP15 and TSPAN9. We also performed
sensitivity analysis under different thresholds (P < 10−4 and P <
10−5) and obtained the similar results (Supplementary Table 6).
Unique and shared pathways in long-term former smokers
We explored Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways in the gene set enrichment analysis of germline-
regulated genes. A total of 53 pathways were significant in long-
term former smokers (Fig. 4f). A total of 18 pathways were shared
across all the subgroups, including the well-known signaling
pathways such as mitogen-activated protein kinase, oxytocin, Ras,
Rap1, and calcium pathways (Fig. 4g). However, 11 pathways were
only significant in long-term former smokers, most of which were
linked to immune function such as the B cell receptor signaling
pathway, human T cell leukemia virus 1 infection, human
immunodeficiency virus 1 infection, and T helper type 1 and T
helper type 2 cell differentiation (Fig. 4h).
DISCUSSION
Understanding genetic risk factors in cancer is important for
uncovering its underlying biological mechanisms11,12. Our genome-
wide investigation among long-term former smokers with NSCLC
Fig. 4 Results of genetic similarity comparative analysis. Similarity comparison of SNPs with P < 10−3 at SNP level (a), germline-regulated
gene level (b), germline-regulated protein-coding gene level (c), eQTL-related gene level (d), enhancer level (e), and KEGG pathway level (f),
respectively. Protein-coding genes were defined by the GENCODE database. g–h Shared and unique KEGG pathways in long-term former
smokers compared with never, short-term former, and current smokers.
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detected rs34211819 in TNS3 and rs1143149 in SEPT7 which were
associated with survival. Significant interactions revealed that the
effects of SNPs could be modified by years of smoking cessation,
perhaps indicating opportunities for clinical adjuvant therapy with
immunotherapies in patients with risk alleles, while an immune
function relationship was found for cis-regulated genes or SNP-
binding proteins. Multi-omics analyses provided evidence of their
eQTL/meQTL relationships, survival-related methylation, and
expression patterns and upregulated proteins in NSCLC. Further-
more, we observed higher similarities between long-term former
smokers and never-smokers, compared to short-term former
smokers or current smokers. The distinct SNP patterns in long-
term former smokers were linked to immune signals.
Tobacco smoking is associated with worse outcomes in lung
cancer, as it leads to downregulation of proinflammatory
cytokines, immunosuppression, and anti-inflammatory effects
mediated by oxidants, carbon monoxide, nicotine, and transcrip-
tional modifying compounds, especially in lung tissues13,14.
Chronic inhalation of cigarette smoke affects a wide range of
immunological functions, including innate and adaptive immune
responses15. As a result, the immune system may be suppressed
as long as individuals are exposed to smoking regardless of years
of quitting or smoking, as evidenced by the same signaling
pathways shared by all the smoking subgroups in our study.
Tobacco smoking can affect the immune system by chemically
modifying signaling pathways as well as the extracellular matrix
through acetylation, nitrosylation, carbonylation, and oxidation,
thereby affecting cell survival, activation, and differentiation16.
The identified genes were associated with NSCLC survival at the
genomic, epigenomic, and transcriptomic levels and were related
to immunological functions. SEPT7 is a member of the septin
family of GTP-binding proteins, which form higher-order filamen-
tous structures and function primarily in spatial organization and
compartmentalization of many cellular processes. SEPT7 is
structurally related to RAS oncogenes, which promote tumorigen-
esis17. SEPT7 is also implicated in several types of cancer18–20.
While the septin family plays a critical role in cytokinesis21, SEPT7 is
also involved in the cytoskeleton and participates in regulation of
cytokinesis22,23. Septin-deficient T cells fail to complete cytokinesis
when prompted by pharmacological activation or cytokines.
Meanwhile, SEPT7-deficient fibroblasts display incomplete cytokin-
esis and constitutive multinucleation by affecting the mitotic
spindle and midbody rather than the contractile ring24. As a result,
SEPT7 plays a crucial role in immune functions including
cytokinesis and mitosis, which are closely related to molecular
changes from smoking exposure.
Another locus at 7p12 is marked by an intronic SNP in TNS3,
which encodes tensin-3, a member of a family of focal adhesion-
associated proteins that regulate cell adhesion and migration25.
This gene may be an activator of cell migration and a promoter of
invasion in tumor metastasis26,27. Here, we found that TNS3 acts as
an oncogene, affecting regulation of methylation in lung cancer. A
TNS3 methylation pattern in the promoter region can silence
expression in renal cell carcinoma28. Further, the binding proteins
BCL3 on 19q13.32 and OCT2 on 19q13.2 of rs34211819 are
strongly linked to immune function. BCL3 translocates to the
immunoglobulin alpha-locus in B cell chronic lymphocytic
leukemia29. As an oncogene, it is an atypical member of the
inhibitor of nuclear factor kappa B (NF-κB) family of proteins that
can activate the NF-κB signaling cascade by directly binding to the
transcription factors NFKB1 and NFKB230. It is unregulated by
cytokines such as tumor necrosis factor alpha, interleukin 4 (IL-4),
IL-1, and IL-631. OCT2 acts as a DNA-binding transcriptional
activator of immunoglobulin in B-lineage cells32. It enables B cells
to respond normally to antigen receptor signals and mediate the
physical interaction with T cells or to produce and respond to
cytokines that are critical drivers of B cell and T cell differentiation
during the immune response31,33.
Genetic similarity analysis of subgroups showed lower overlap
at the SNP level but relatively higher overlap of germline-
regulated genes. It is possible that each SNP is unique to each
subgroup and acts as an eQTL to regulate cancer-specific genes.
Additionally, the effects of somatic mutations driving lung cancer
should be investigated. We also found higher similarities between
long-term former smokers and never-smokers, which mainly
included inflammation and immune mechanisms, as reported in
the previous studies10,34.
This study had some limitations. First, although we used the
largest lung cancer consortium to date, further external cohort
validation with follow-up information and smoking cessation
details is warranted. Second, we selected SNPs with moderate
association strengths (from P < 10−5 to P < 10−3); although it was a
reasonable approach35,36, some false-positive SNPs may have
been included. More well-designed functional experiments are
necessary to validate the biological functions.
This study also had several strengths. To the best of our
knowledge, this is the first GWAS to investigate the effects of
genetic variants on NSCLC patients among long-term former
smokers. We included a large and relatively homogeneous study
population with relatively complete and accurate follow-up,
demographic, and clinical covariate information from ILCCO and
HLCS. In addition, we investigated the association of candidate
genes and lung cancer at the multi-omics levels, including
genomics, transcriptomics, epigenomics, and proteomics. Similar-
ity comparisons among different smoking subgroups revealed the
shared genetics status at multiple levels.
In summary, our study demonstrated that TNS3 at 7p12.3 and
SEPT7 at 7p14.2 are genetic regions associated with survival
among long-term former smokers, and the findings with subgroup
were related to immune function. Our results may shed light on
the important roles of genetic architecture on cancer outcomes
among long-term former smokers with NSCLC, a subpopulation
that has been less studied.
METHODS
Study population
In accordance with the previous studies37–39, long-term former smokers
were defined as patients who quitted smoking at least 10 years before
diagnosis, whereas short-term former smokers quitted <10 years before
diagnosis, and never smokers were those who smoked <100 cigarettes
during their lifetime. To identify prognostic SNPs, we focused on long-term
former smokers, whose characteristics are presented in Table 1. Patients in
the discovery set were recruited from ILCCO, including the Cancer de
Pulmon en Asturias study, Carotene and Retinol Efficacy Trial (CARET),
Liverpool Lung Cancer Project, MD Anderson Cancer Center Study, and
Mount-Sinai Hospital-Princess Margaret Study. While, patients in the
independent validation set were recruited from HLCS (Supplementary
Information). Approval for ILCCO studies was obtained from each of the
participating institutional research ethics review boards. For HLCS, the
Institutional Review Board of MGH and the Human Subjects Committee of
the Massachusetts General Hospital and Harvard School of Public Health
approved the study. All the participants were provided written informed
consent to take part in the study.
Of the 6129 NSCLC patients with follow-up information totally, 4351
eligible cases were with available smoking information, including 504
never smokers, 1299 long-term former smokers, 687 short-term former
smokers, and 1861 current smokers (Supplementary Table 7).
OncoArray genotype quality control and imputation
The ILCCO study and HLCS were originally designed and genotyped as
case–control studies of lung cancer risk. In this study, we extracted all
NSCLC patients from these two studies with survival information. Patient
genotypes were generated using the Infinium OncoArray-500k BeadChip
(Illumina, San Diego, CA, USA), with standard quality control procedures
performed on all eligible individuals. Briefly, excluded were samples with
<95% completion and SNP assays with call rates <95% or deviating from
Hardy–Weinberg equilibrium (P < 10−6). Only SNPs with minor allele
S Shen et al.
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frequencies (MAFs) ≥ 0.05 mapping to autosomal chromosomes were
included in the analysis. A total of 416,861 SNPs passed quality control40.
Genome-wide imputation following the Michigan Imputation Server
pipeline41 was performed to estimate missing genotype information. We
phased haplotypes with Eagle v2.3 using 1000 Genomes Project data
(phase 3) as a reference panel42 and then performed imputations using the
Minimac (version 3) software. SNPs with an imputation quality score R2 <
0.8, MAF < 0.05, or P < 10−6 for the Hardy–Weinberg equilibrium test were
excluded from analyses.
Two-stage GWAS survival analysis
We used a two-stage strategy to identify significant prognostic SNPs for
NSCLC patients who were long-term former smokers (Fig. 5). SNPs were
encoded with an additive model (0: wild type; 1: heterozygosity; 2:
homozygosity), unless otherwise stated. To quantify the association of
each SNP with survival, we used the Cox proportional hazards regression
model to evaluate its effect on survival, after adjusting for age, gender,
clinical stage (I–IV), histology, pack-years of smoking, years of smoking
cessation, and study center. Hazard ratio (HR) and 95% confidence interval
(CI) were described for mortality risk for patients per minor allele carried.
To control for the confounding effects of population stratification, we also
performed principal component analysis (PCA) and included the first three
principal components in the model, although no population stratification
was observed in the PCA plot (Supplementary Fig. 2). Following the same
selection criteria commonly used in the previous GWAS survival studies of
cancers43,44, we defined significant SNPs as those that met the following
criteria: (i) P ≤ 10−5 in the discovery set; (ii) P ≤ 0.05 in the validation set;
and (iii) P ≤ 5×10−8 in the combined set, reaching genome-wide
significance. Kaplan-Meier curves were generated to illustrate survival
differences between groups with different SNP genotypes, DNA methyla-
tion levels or gene expression levels.
Gene–environment interaction analysis
Since these SNPs significantly associated with prognosis of long-term
former smokers with NSCLC, we further conducted gene–environment
interaction analysis by estimating how their effects varied with increased
years of smoking cessation. Specifically, we included the interaction terms
between these SNPs and years of smoking cessation in the Cox
proportional hazards regression model adjusted for the same covariates
aforementioned.
Multi-omics analysis
We evaluated gene expression, DNA methylation of these significant SNPs,
and further performed in silico function prediction and protein analysis.
To examine the eQTL relationships between SNPs and the expression
levels of the corresponding genes, we evaluated their associations by
using both the summary-level data from 383 lung tissue samples through
the GTEx portal (V7 release)45 and the individual-level data from 208
NSCLC Caucasian patients who were long-term former smokers in The
Cancer Genome Atlas (TCGA) database (Supplementary Table 8). The cis-
eQTL information in GTEx including normalized effect size, standard error,
and nominal p value for each SNP-expression pair was collected. Genotype
data from TCGA were collected from the GDC Legacy Data Portal (Level 2,
birdseed data), which were generated from Affymetrix Genome-Wide
Fig. 5 Study workflow. Our study mainly included three parts: (1) GWAS survival study for long-term former smokers; (2) multi-omics study
for candidate SNPs and genes; and (3) genetic similarity comparative analysis among different smoking status subgroups.
Table 1. Demographic and clinical characteristics of long-term former
smoking NSCLC patients.
Characteristics Discovery set Validation set Combined set
Sample size 566 733 1,299
Deaths (%) 387 (68.4) 500 (68.2) 887 (68.2)
Median survival
years (95% CI)
2.14 (1.71–2.51) 2.87 (2.69–3.31) 2.64 (2.38–2.86)
Age (years) 70.98 ± 8.79 70.01 ± 9.22 70.43 ± 9.04
Gender, male (%) 373 (65.9) 385 (52.5) 758 (58.4)
Histology (%)
LUSC 194 (61.4) 137 (18.7) 331 (25.5)
LUAD 348 (34.2) 529 (72.2) 877 (67.5)
NSCLC, not
specified
24 (4.2) 67 (9.1) 91 (7)
Clinical stage (%)
I 207 (36.5) 258 (35.2) 465 (35.8)
II 68 (12.0) 72 (9.8) 140 (10.8)
III 131 (23.1) 165 (22.5) 296 (22.8)
IV 138 (24.3) 228 (31.1) 366 (28.2)
Pack-years of
smoking
36.49 ± 29.00 37.49 ± 29.03 37.05 ± 29.01
Years of smoking
cessation
23.18 ± 10.49 23.66 ± 10.39 23.45 ± 10.44
LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, NSCLC
non-small cell lung cancer.
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Human SNP 6.0 Array. We performed the same quality control and
imputation procedures as aforementioned. Gene expression values were
normalized using the RNA-seq by expectation–maximization method46,
and dichotomized, when needed, into low- and high-expression sub-
groups by the median values. To summarize the eQTL effects from TCGA
and GTEx, we used meta-analysis with the fixed-effects model. The Cox
proportional hazards regression model adjusted for the same covariates as
aforementioned was utilized to evaluate the prognostic effects of gene
expressions in tumor tissues in TCGA.
The association between SNP and DNA methylation was tested among
155 Caucasian patients who were long-term former smokers in TCGA. DNA
methylation data were profiled using Illumina HumanMethylation450
BeadChips. The details of quality control were described in47. We used the
linear regression model to assess meQTL effects and the Cox proportional
hazards regression model to evaluate the association between methylation
CpG probes (dichotomized by the median values) and survival. These
models were adjusted for the same covariates. False discovery rate
adjusted P value (q value) was used to correct for multiple comparisons.
We used an in silico approach through SNPinfo48, RegulomeDB49, and
HaploReg v4.150 to predict potential functions of the identified SNPs. We
also compared protein levels among the 101 tumors paired with normal
adjacent lung cancer tissue samples using Student’s paired t test in the
Clinical Proteomic Tumor Analysis Consortium (CPTAC) project51. The data
were normalized following the CPTAC Common Data Analysis Pipeline.
Genetic similarity comparative analysis
To assess genetic similarity of long-term former smoking patients with
other smoking subgroups (e.g., never, short-term former, and current
smokers), we performed GWAS survival analysis within each smoking
subgroup using the Cox proportional hazards regression model adjusted
for the same covariates aforementioned. We selected SNPs with moderate
association strengths (P < 1 × 10−3)36. Genetic similarity comparisons were
made at the SNP, gene, eQTL, enhancer, and pathway levels, respectively.
For gene-level analyses, germline-regulated genes were defined as the
nearest genes using the Ensembl definitions on genome build GRCh37
(hg19), which annotated the genomic locations for each subgroup using
gene start and stop coordinates52. All gene features were defined by
GENCODE V2553. We kept SNPs with no strong linkage disequilibrium (LD)
using the PLINK indep-pairwise function; the r2 used for all LD trimming was
0.5. eQTLs were collected from GTEx lung tissues as described above.
For enhancer-level analysis, the FANTOM5 human enhancer database
was used to identify enhancer activities across most cell types and
tissues54. SNPs located within a permissive enhancer region ±1 kb were
defined as the enhancer-related variants.
For pathway-level analysis, we performed gene enrichment pathway
analysis based on the KEGG database. All enrichment analyses were
performed using the R package clusterProfiler55.
All statistical analyses were performed using R (v3.5.2) or PLINK (v1.9).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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tary Table 4) are available from the HaploReg website https://pubs.broadinstitute.org/
mammals/haploreg/haploreg.php. De-identified participant demographic and pheno-
type data for lung adenocarcinoma patients are available from the National Cancer
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